Kerstin Hansson

Title: Kerstin Hansson: Innovator in Dysglucaemia Treatment

Introduction

Kerstin Hansson is a notable inventor based in Lund, Sweden. She has made significant contributions to the field of medical treatments, particularly focusing on dysglucaemia. With two patents to her name, her work is aimed at improving the quality of life for patients suffering from this condition.

Latest Patents

Kerstin's latest patents revolve around a composition and method for the treatment of dysglucaemia. This innovative approach involves the administration of granulated starch that is enzymatically degraded to release reducing sugars at a rate tailored to the metabolism of the patient. For instance, her method helps prevent nocturnal hypoglycaemia in diabetic patients by administering granulate or tablets containing granulated cornstarch, heat-treated cornstarch, and a low-calorie sweetener. The granulation process minimizes the available surface area, retards enzymatic degradation, and ensures a controlled release of reducing sugars, such as glucose, maintaining stable blood glucose levels for several hours. Importantly, the granulate or tablets are low in calories and contain no free sugar.

Career Highlights

Kerstin Hansson is associated with Metcon Medicin AB, where she continues to develop her innovative treatments. Her work has garnered attention for its potential to significantly impact the management of dysglucaemia.

Collaborations

Kerstin collaborates with notable colleagues, including Henri Hansson and Mats Lake, who contribute to her research and development efforts.

Conclusion

Kerstin Hansson's contributions to the treatment of dysglucaemia through her innovative patents highlight her role as a leading inventor in the medical field. Her work not only addresses a critical health issue but also showcases the importance of innovation in improving patient care.